SPPI•benzinga•
HC Wainwright & Co. Maintains Buy Rating for Spectrum Pharmaceuticals: Here's What You Need To Know
Summary
HC Wainwright & Co. has decided to maintain its Buy rating of Spectrum Pharmaceuticals (NASDAQ:SPPI) and raise its price target from $10.00 to $12.00. Shares of Spectrum Pharmaceuticals are trading up 5.79% over the last 24 hours, at $1.37 per share.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga